News Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Market Closed - Canadian Securities Exchange Other stock markets 12:12:10 08/05/2024 am IST			5-day change	1st Jan Change
0.195 ^CAD	-7.14%		0.00%	+34.48%

03/04	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
03/04	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ	08/05	NE
Canadian Investment Regulatory Organization Trading Halt - AWKN	08/05	AQ
Awakn Life Sciences Discusses Filing of Financial Statements	03/05	NE
Awakn Life Sciences Announces Closing of Tranche of Private Placement	17/04	NE
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic	03/04	NE
Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	03/04	CI
Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	03/04	CI
Canadian Securities Exchange Reports February 2024 Performance Figures	15/03	NE
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)	13/02	NE
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange	12/02	NE
Awakn Life Sciences Announces Conditional Approval of CSE Listing	05/02	NE
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market	24/01	CI
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers	24/01	NE
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG	20/12	CI
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS	20/12	NE
Awakn Life Sciences Provides Corporate Update	15/12	NE
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	15/12	CI
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder	15/11	CI
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001	15/11	NE
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements	11/11	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Summary

Filters